The United States food and Drug Administration(FDA)in today's time, announced approval of the first kind for anti-viral agents Andexxa market, for the treatment due to the use of a variety of inhibiting Factor Xa drugs(Rivaroxaban xarelto ,and Apixaban on coagulation,Dabigatran up to a hundred students) is a life-threatening situation or cannot control bleeding, the FDA approved Portola Pharmaceuticals pharmaceuticals products in the United States market for sale.

Andexxa anti-viral agents is a synthetic protein fragment, its role and types of inhibition of Factor Xa drugs in combination, so that the body is full Factor Xa from inhibition and exerts its biological characteristics, and this new drug is mainly for is Rivaroxaban and Apixaban because they are currently also no formal antidote, while Dabigatran has its own pharmaceutical factory in the development of idarucizumab as an antidote, but its source is a monoclonal antibody, so according to the immunological idarucizumab organic will cause body hypersensitivity.

Andexxa in getting FDA approval to market will be in 2019 to 2023 market tracking survey(4 clinical), and the FDA also in this pharmaceutical on the box-shaped label because of its possible side effects include thromboembolism, ischemic risk of cardiac arrest and sudden death. And Andexxa in clinical practice when there is 5%of the patients with urinary tract infections and the pneumonia of adverse reactions.